Our Viral Sensitizer technology consists of a library of over one hundred small molecules that can safely overcome the natural immunological defences in the human and animal body that suppress effective viral medicines.
When immune responses are safely reduced, targeted infection by medicinal viruses can improve. This has a number of practical and sought-out applications that positively contribute to public health goals and better clinical care.
We first identified our novel Viral Sensitizers by employing an innovative high-throughput screening process. Virica continues to employ this cutting-edge equipment and can identify the most synergistic Viral Sensitizer molecules from our library for any virus strain.
We can tailor formulations of our Viral Sensitizers to boost virus yield in your manufacturing facility or improve the effects of your viral therapies.
When immune responses are safely reduced, targeted infection by medicinal viruses can improve. This has a number of practical and sought-out applications that positively contribute to public health goals and better clinical care.
We first identified our novel Viral Sensitizers by employing an innovative high-throughput screening process. Virica continues to employ this cutting-edge equipment and can identify the most synergistic Viral Sensitizer molecules from our library for any virus strain.
We can tailor formulations of our Viral Sensitizers to boost virus yield in your manufacturing facility or improve the effects of your viral therapies.
Location: Canada, Ontario, (Old) Ottawa
Employees: 11-50
Founded date: 2018
Investors 1
| Date | Name | Website |
| - | Capital An... | capitalang... |
Mentions in press and media 5
| Date | Title | Description |
| 30.10.2024 | Virica Biotech is Building an Ecosystem to Ramp Up AAV Production | Portfolio company Virica Biotech made two recent collaboration announcements highlighting the industry embracing their cell enhancing platform for improving adeno-associated vectors (AAVs) production. Virica and eXmoor Pharma announced a ne... |
| 11.04.2024 | Virica Biotech Selected as a Lead Project as Part of NIIMBL's $10M Biomanufacturing Projects | Portfolio company, Virica Biotech has been included in a NIIMBL (The National Institute for Innovation in Manufacturing Biopharmaceuticals) $10M program as a lead project in a total of 8 biomanufacturing Projects. Virica's VSE platform help... |
| 24.05.2023 | Viral Vector Manufacturing — Are Antiviral Defenses the Missing Link to Scalability? Upcoming Webinar Hosted by Xtalks | The growing interest in unraveling viral vector quality metrics beyond yield increase via raw titers will be discussed, with an emphasis on the importance of functional viral yield. TORONTO, Ontario (PRWEB) May 24, 2023 Viral-based gene the... |
| 27.10.2022 | Process Intensification in AAV Gene Therapy, Upcoming Webinar Hosted by Xtalks | One of the major bottlenecks, addressed in this webinar, is the problem of low manufacturing yield. TORONTO (PRWEB) October 27, 2022 Gene therapy holds the potential to dramatically change healthcare for the better. Many of these viral ther... |
| - | Virica Biotech | “Viral Sensitizers (VSE) for drug developers and manufacturers are small molecules that improve viral yields and effectiveness by reducing the antiviral defences on a cellular level.” |